26 August 2015Americas

US and Brazil clear path for Pfizer’s Hospira buyout

Pfizer’s buyout of Hospira, which is set to boost Pfizer’s biosimilars portfolio but has been the subject of anti-competition concerns, will be completed next month after gaining final approval.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

European Commission approves Pfizer’s buyout of Hospira

6 August 2015 The European Commission has approved US pharmaceutical company Pfizer’s $17 billion acquisition of Hospira, a move that will see Pfizer acquire the drugs company’s biosimilar portfolio.

Americas

Pfizer’s Hospira buyout approved in Australia and Canada

18 August 2015 Pfizer’s $17 billion buyout of Hospira has been approved in Canada and Australia after the countries’ competition bureaus approved the deal.

Americas

Hospira patent dispute revived

14 September 2015 A US appeals court has revived a dispute in which a lower court previously ruled that there should not be a trial to determine whether pharmaceutical company Hospira infringed three patents.

More on this story

Americas

European Commission approves Pfizer’s buyout of Hospira

Americas

Pfizer’s Hospira buyout approved in Australia and Canada

18 August 2015 Pfizer’s $17 billion buyout of Hospira has been approved in Canada and Australia after the countries’ competition bureaus approved the deal.

Americas

Hospira patent dispute revived

More on this story

Americas

European Commission approves Pfizer’s buyout of Hospira

Americas

Pfizer’s Hospira buyout approved in Australia and Canada

18 August 2015 Pfizer’s $17 billion buyout of Hospira has been approved in Canada and Australia after the countries’ competition bureaus approved the deal.

Americas

Hospira patent dispute revived